US Eastern Timezone Humanetics - Oral Agent to Combat Alzheimer's Disease

MINNEAPOLIS--(BUSINESS WIRE)
--Dec. 1, 2005--
Humanetics Corporation today announced that it has entered into an exclusive license agreement with Mount Sinai School of Medicine in Manhattan, NY to further develop and commercialize an oral agent, referenced as NIC5-15, to combat Alzheimer's disease. This compound has been shown in pre-clinical studies and animal models to be effective in preventing the formation of beta amyloid plaques, which are believed to be a cause of Alzheimer's disease. Humanetics also announced that it has entered into a clinical research agreement with investigators at Mount Sinai to test the effect of the compound in humans. The Principal Investigator on the study is Giulio Maria Pasinetti, M.D., Ph.D., in the Department of Psychiatry and Department of Neurosciences at Mount Sinai.